Biotechnology companies spend years figuring out the right combination of mutant host organism and reactor conditions to fashion a proteintherapy that is safe and effective.
Therefore, inhibiting polyglutamine protein aggregation or deposition would be an important target for HD therapy.
多聚谷氨酰氨的聚集、沉淀可能是该病发病的原因和关键。
3
This fall, the startup company Tivorsan Pharmaceuticals licensed rights from Brown to the key protein, biglycan, hoping to bring the potential therapy through clinical trials.